Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Multi-center, prospective randomised phase III study evaluating capecitabine in combination
with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in
patients with metastatic renal cell carcinoma.